Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

NCT00514683 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

432

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Fibrosis

Interventions

DRUG: low dose BIBF1120 once daily
DRUG: low dose BIBF 1120 twice daily
DRUG: intermediate dose BIBF 1120 twice daily
DRUG: high dose BIBF 1120 twice daily
DRUG: placebo

Sponsor

Boehringer Ingelheim